Targeting the miR-96-5p/Cathepsin B Pathway to Alleviate Neuron-Derived Neuroinflammation in Alzheimer's Disease

Abstract

Alzheimer's disease (AD) is one of the leading causes of dementia in the elderly, and no effective treatment is currently available. Cathepsin B (CTSB) is involved in key pathological processes of AD, but the underlying mechanisms and its relevance to AD diagnosis and treatment remain unclear. In the present study, we found that CTSB expression was abnormally elevated in the hippocampus of 3×Tg mice and was regulated by miR-96-5p. Abnormalities in the miR-96-5p/CTSB signaling pathway were detected in the serum of both mild cognitive impairment and AD patients, and the combination of serum miR-96-5p and CTSB demonstrated strong diagnostic efficacy for cognitive impairment (AUC = 0.7536). Abnormalities in the miR-96-5p/CTSB signaling pathway in AD may be associated with Aβ pathology, and neuronal CTSB can be released extracellularly to reactivate adjacent astrocytes. Ultimately, the reconstitution of the miR-96-5p/CTSB signaling pathway effectively rescued astrocyte reactivity and memory impairment in AD. Our findings suggest that the neuron-derived inflammatory mediator CTSB reactivates adjacent astrocytes and mediates memory impairment in early AD. The combination of serum miR-96-5p and CTSB represents potential serum biomarkers for cognitive impairment, and targeting the neuronal miR-96-5p/CTSB pathway may serve as a promising therapeutic strategy for AD.

Keywords

Alzheimer's disease / cathepsin B / miR-96 / neuroinflammation / potential serum biomarker

References

[1] S. Thakral, A. Yadav, V. Singh, et al., “Alzheimer's Disease: Molecular Aspects and Treatment Opportunities Using Herbal Drugs,” Ageing Research Reviews 88 (2023): 101960.

[2] K. Grossmann, “Unraveling the Thrombin-Alzheimer's Connection: Oral Anticoagulants as Potential Neuroprotective Therapeutics,” Advanced Neurology 3 (2024): 3799.

[3] M. Simons, J. Levin, and M. Dichgans, “Tipping Points in Neurodegeneration,” Neuron 111 (2023): 2954-2968.

[4] D.-Y. Liu, H.-Z. Huang, K. Li, Y. Lu, and L.-Q. Zhu, “EPAC2 knockout Causes Abnormal Tau Pathology Through Calpain-mediated CDK5 Activation,” Advanced Neurology 1 (2022): 8.

[5] S. Thakur, R. Dhapola, P. Sarma, B. Medhi, and D. H. Reddy, “Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics,” Inflammation 46 (2023): 1-17.

[6] H. Nakanishi, “Cathepsin Regulation on Microglial Function,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1868 (2020): 140465.

[7] M. I. Hossain, J. M. Marcus, J. H. Lee, et al., “Restoration of CTSD (cathepsin D) and Lysosomal Function in Stroke Is Neuroprotective,” Autophagy 17 (2021): 1330-1348.

[8] G. Hook, T. Reinheckel, J. Ni, et al., “Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders,” Pharmacological Reviews 74 (2022): 600-629.

[9] Z. Xie, J. Meng, W. Kong, et al., “Microglial Cathepsin E Plays a Role in Neuroinflammation and Amyloid β Production in Alzheimer's Disease,” Aging Cell 21 (2022): e13565.

[10] Y. Bouter, T. Kacprowski, R. Weissmann, et al., “Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer's Disease by Deep Sequencing,” Frontiers in Aging Neuroscience 6 (2014): 75.

[11] Y. Sun, X. Rong, W. Lu, et al., “Translational Study of Alzheimer's Disease (AD) Biomarkers From Brain Tissues in AβPP/PS1 Mice and Serum of AD Patients,” Journal of Alzheimer's Disease 45 (2015): 269-282.

[12] A. Sharma, R. Swetha, N. G. Bajad, et al., “Cathepsin B-A Neuronal Death Mediator in Alzheimer's Disease Leading to Neurodegeneration,” Mini - Reviews in Medicinal Chemistry 22 (2022): 2012-2023.

[13] V. Y. H. Hook, “Unique Neuronal Functions of Cathepsin L and Cathepsin B in Secretory Vesicles: Biosynthesis of Peptides in Neurotransmission and Neurodegenerative Disease,” Biological Chemistry 387 (2006): 1429-1439.

[14] Z. Wu, J. Ni, Y. Liu, et al., “Cathepsin B Plays a Critical Role in Inducing Alzheimer's Disease-Like Phenotypes Following Chronic Systemic Exposure to Lipopolysaccharide From Porphyromonas gingivalis in Mice,” Brain, Behavior, and Immunity 65 (2017): 350-361.

[15] G. Hook, J. Yu, T. Toneff, M. Kindy, and V. Hook, “Brain Pyroglutamate Amyloid-β Is Produced by Cathepsin B and Is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic,” Journal of Alzheimer's Disease 41 (2014): 129-149.

[16] M. S. Kindy, J. Yu, H. Zhu, S. S. El-Amouri, V. Hook, and G. R. Hook, “Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic ALZHeimer's disease Mouse Model Expressing AβPP Containing the Wild-type β-secretase Site Sequence,” Journal of Alzheimer's Disease 29 (2012): 827-840.

[17] A. M. Cataldo and R. A. Nixon, “Enzymatically Active Lysosomal Proteases Are Associated With Amyloid Deposits in Alzheimer Brain,” Proceedings of the National Academy of Sciences 87 (1990): 3861-385.

[18] K. Yuyama, H. Sun, R. Fujii, I. Hemmi, K. Ueda, and Y. Igeta, “Extracellular Vesicle Proteome Unveils Cathepsin B Connection to Alzheimer's Disease Pathogenesis,” Brain 147 (2024): 627-636.

[19] S. S. Hébert, K. Horré, L. Nicolaï, et al., “Loss of microRNA Cluster miR-29a/b-1 in Sporadic Alzheimer's Disease Correlates With Increased BACE1/Beta-secretase Expression,” Proceedings of the National Academy of Sciences 105 (2008): 6415-6420.

[20] K. Zheng, F. Hu, Y. Zhou, et al., “miR-135a-5p Mediates Memory and Synaptic Impairments via the Rock2/Adducin1 Signaling Pathway in a Mouse Model of Alzheimer's Disease,” Nature Communications 12 (2021): 1903.

[21] Z. Dong, H. Gu, Q. Guo, et al., “Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer's Disease,” Molecular Neurobiology 58 (2021): 3084-3094.

[22] C. Peña-Bautista, A. Tarazona-Sánchez, A. Braza-Boils, et al., “Plasma microRNAs as Potential Biomarkers in Early Alzheimer Disease Expression,” Scientific Reports 12 (2022): 15589.

[23] E. Bayam, G. S. Sahin, G. Guzelsoy, G. Guner, A. Kabakcioglu, and G. Ince-Dunn, “Genome-wide Target Analysis of NEUROD2 Provides New Insights Into Regulation of Cortical Projection Neuron Migration and Differentiation,” BMC Genomics [Electronic Resource] 16 (2015): 681.

[24] X. Fei, Y.-N. Dou, L. Wang, et al., “Homer1 promotes the Conversion of A1 Astrocytes to A2 Astrocytes and Improves the Recovery of Transgenic Mice After Intracerebral Hemorrhage,” Journal of Neuroinflammation 19 (2022): 67.

[25] Z. Meng, M. Gao, C. Wang, S. Guan, D. Zhang, and J. Lu, “Apigenin Alleviated High-Fat-Diet-Induced Hepatic Pyroptosis by Mitophagy-ROS-CTSB-NLRP3 Pathway in Mice and AML12 Cells,” Journal of Agricultural and Food Chemistry 71 (2023): 7032-7045.

[26] M. Montaser, G. Lalmanach, and L. Mach, “CA-074, but Not Its Methyl Ester CA-074Me, Is a Selective Inhibitor of Cathepsin B Within Living Cells,” Biological Chemistry 383 (2002): 1305-1308.

[27] E. Inoue, S. Minatozaki, S. Shimizu, et al., “Human β-Defensin 3 Inhibition of P. gingivalis LPS-Induced IL-1β Production by BV-2 Microglia Through Suppression of Cathepsins B and L,” Cells 13 (2024): 283.

[28] V. Hook, M. Yoon, C. Mosier, et al., “Cathepsin B in Neurodegeneration of Alzheimer's Disease, Traumatic Brain Injury, and Related Brain Disorders,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1868 (2020): 140428.

[29] D. Singh, “Astrocytic and Microglial Cells as the Modulators of Neuroinflammation in Alzheimer's Disease,” Journal of Neuroinflammation 19 (2022): 206.

[30] L. Wu, Y. Liu, Q. He, et al., “PEDF-34 Attenuates Neurological Deficit and Suppresses Astrocyte-dependent Neuroinflammation by Modulating Astrocyte Polarization via 67LR/JNK/STAT1 Signaling Pathway After Subarachnoid Hemorrhage in Rats,” Journal of Neuroinflammation 21 (2024): 178.

[31] L. A. Welikovitch, S. Do Carmo, Z. Maglóczky, et al., “Early Intraneuronal Amyloid Triggers Neuron-Derived Inflammatory Signaling in APP Transgenic Rats and Human Brain,” Proceedings of the National Academy of Sciences 117 (2020): 6844-6854.

[32] J. Wang, L. Wang, X. Zhang, et al., “Cathepsin B Aggravates Acute Pancreatitis by Activating the NLRP3 Inflammasome and Promoting the Caspase-1-Induced Pyroptosis,” International Immunopharmacology 94 (2021): 107496.

[33] Y. Jin, C. Wang, Z. Meng, et al., “Proanthocyanidins Alleviate Acute Alcohol Liver Injury by Inhibiting Pyroptosis via Inhibiting the ROS-MLKL-CTSB-NLRP3 Pathway,” Phytomedicine 136 (2025): 156268.

[34] P. P. Rose, M. Bogyo, A. V. Moses, and K. Früh, “Insulin-Like Growth Factor II Receptor-Mediated Intracellular Retention of Cathepsin B Is Essential for Transformation of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus,” Journal of Virology 81 (2007): 8050-8062.

[35] J. Ni, Z. Wu, C. Peterts, K. Yamamoto, H. Qing, and H. Nakanishi, “The Critical Role of Proteolytic Relay Through Cathepsins B and E in the Phenotypic Change of Microglia/Macrophage,” Journal of Neuroscience 35 (2015): 12488-12501.

[36] J. Lu, H. Li, Z. Yu, et al., “Cathepsin B as a Key Regulator of Ferroptosis in Microglia Following Intracerebral Hemorrhage,” Neurobiology of Disease 194 (2024): 106468.

[37] H. Nakanishi, K. Tominaga, T. Amano, I. Hirotsu, T. Inoue, and K. Yamamoto, “Age-related Changes in Activities and Localizations of Cathepsins D, E, B, and L in the Rat Brain Tissues,” Experimental Neurology 126 (1994): 119-128.

[38] M. Yoshida, T. Yamashima, L. Zhao, et al., “Primate Neurons Show Different Vulnerability to Transient Ischemia and Response to Cathepsin Inhibition,” Acta Neuropathologica 104 (2002): 267-272.

[39] S. Liu, P. Perez, X. Sun, et al., “MLKL Polymerization-induced Lysosomal Membrane Permeabilization Promotes Necroptosis,” Cell Death and Differentiation 31 (2024): 40-52.

[40] A. P. Tran, S. Sundar, M. Yu, B. T. Lang, and J. Silver, “Modulation of Receptor Protein Tyrosine Phosphatase Sigma Increases Chondroitin Sulfate Proteoglycan Degradation Through Cathepsin B Secretion to Enhance Axon Outgrowth,” Journal of Neuroscience 38 (2018): 5399-5414.

[41] T. Schlüter, C. Berger, E. Rosengauer, et al., “miR-96 Is Required for Normal Development of the Auditory Hindbrain,” Human Molecular Genetics 27 (2018): 860-874.

[42] C. Kinoshita, K. Aoyama, N. Matsumura, K. Kikuchi-Utsumi, M. Watabe, and T. Nakaki, “Rhythmic Oscillations of the microRNA miR-96-5p Play a Neuroprotective Role by Indirectly Regulating Glutathione Levels,” Nature Communications 5 (2014): 3823.

[43] V. Hook, T. Toneff, M. Bogyo, et al., “Inhibition of Cathepsin B Reduces Beta-amyloid Production in Regulated Secretory Vesicles of Neuronal Chromaffin Cells: Evidence for Cathepsin B as a Candidate Beta-secretase of Alzheimer's Disease,” Biological Chemistry 386 (2005): 931-940.

[44] A. A. Siddiqui, E. Merquiol, R. Bruck-Haimson, et al., “Cathepsin B Promotes Aβ Proteotoxicity by Modulating Aging Regulating Mechanisms,” Nature Communications 15 (2024): 8564.

[45] G. M. Mórotz, E. B. Glennon, P. Gomez-Suaga, et al., “LMTK2 binds to Kinesin Light Chains to Mediate Anterograde Axonal Transport of cdk5/p35 and LMTK2 Levels Are Reduced in Alzheimer's disease Brains,” Acta Neuropathology Communications 7 (2019): 73.

[46] K. Runge, R. Mathieu, S. Bugeon, et al., “Disruption of NEUROD2 Causes a Neurodevelopmental Syndrome With Autistic Features via Cell-Autonomous Defects in Forebrain Glutamatergic Neurons,” Molecular Psychiatry 26 (2021): 6125-6148.

[47] S. A. Wilke, B. J. Hall, J. K. Antonios, et al., “NeuroD2 regulates the Development of Hippocampal Mossy fiber Synapses,” Neural Development 7 (2012): 9.

[48] A. P. Fong, Z. Yao, J. W. Zhong, et al., “Genetic and Epigenetic Determinants of Neurogenesis and Myogenesis,” Developmental Cell 22 (2012): 721-735.

[49] B. Dubois, C. A. F. von Arnim, N. Burnie, S. Bozeat, and J. Cummings, “Biomarkers in Alzheimer's Disease: Role in Early and Differential Diagnosis and Recognition of atypical Variants,” Alzheimer's Research Therapy 15 (2023): 175.

[50] T. X. Lu and M. E. Rothenberg, “MicroRNA,” Journal of Allergy and Clinical Immunology 141 (2018): 1202-1207.

[51] M.-L. Chen, C.-G. Hong, T. Yue, et al., “Inhibition of miR-331-3p and miR-9-5p Ameliorates Alzheimer's Disease by Enhancing Autophagy,” Theranostics 11 (2021): 2395-2409.

[52] H. Z. Y. Wu, A. Thalamuthu, L. Cheng, et al., “Differential Blood miRNA Expression in Brain Amyloid Imaging-defined Alzheimer's Disease and Controls,” Alzheimer's Research Therapy 12 (2020): 59.

[53] A. Vallelunga, T. Iannitti, S. Capece, et al., “Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease,” Frontiers in Aging Neuroscience 13 (2021): 632891.

[54] G. Chang, W. Zhang, M. Zhang, and G. Ding, “Clinical Value of Circulating ZFAS1 and miR-590-3p in the Diagnosis and Prognosis of Chronic Heart Failure,” Cardiovascular Toxicology 21 (2021): 880-888.

[55] D. Xie, Y. Chen, X. Wan, et al., “The Potential Role of CDH1 as an Oncogene Combined with Related miRNAs and Their Diagnostic Value in Breast Cancer,” Frontiers in Endocrinology (Lausanne) 13 (2022): 916469.

[56] O. Hansson, K. Blennow, H. Zetterberg, and J. Dage, “Blood Biomarkers for Alzheimer's Disease in Clinical Practice and Trials,” Nature Aging 3 (2023): 506-519.

[57] S. Bun, D. Ito, T. Tezuka, et al., “Performance of Plasma Aβ42/40, Measured Using a Fully Automated Immunoassay, Across a Broad Patient Population in Identifying Amyloid Status,” Alzheimer's Research Therapy 15 (2023): 149.

[58] X. Zhong, Q. Wang, M. Yang, et al., “Plasma p-tau217 and p-tau217/Aβ1-42 Are Effective Biomarkers for Identifying CSF- and PET Imaging-Diagnosed Alzheimer's Disease: Insights for Research and Clinical Practice,” Alzheimer's & Dementia 21 (2025): e14536.

[59] P. Oeckl, S. Anderl-Straub, C. A. F. Von Arnim, et al., “Serum GFAP Differentiates Alzheimer's Disease From Frontotemporal Dementia and Predicts MCI-to-Dementia Conversion,” Journal of Neurology, Neurosurgery, and Psychiatry (2022).

[60] X. Wang, D. Liu, H.-Z. Huang, et al., “A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease,” Biological Psychiatry 83 (2018): 395-405.

[61] A.-J. Xie, T.-Y. Hou, W. Xiong, et al., “Tau Overexpression Impairs Neuronal Endocytosis by Decreasing the GTPase Dynamin 1 Through the miR-132/MeCP2 Pathway,” Aging Cell 18 (2019): e12929.

[62] L.-T. Zhou, D. Liu, H.-C. Kang, et al., “Tau Pathology Epigenetically Remodels the Neuron-Glial Cross-Talk in Alzheimer's Disease,” Science Advances 9 (2023): eabq7105.

[63] Y. Peng, M. Zhang, L. Zheng, et al., “Cysteine Protease Cathepsin B Mediates Radiation-Induced Bystander Effects,” Nature 547 (2017): 458-462.

[64] H.-Z. Huang, X. Wang, and D. Liu, “Cognition Damage Due to Disruption of Cyclic Adenosine Monophosphate-Related Signaling Pathway in Melatonin Receptor 2 Knockout Mice,” Advanced Neurology 2 (2023): 0974.

[65] D. Liu, H. Tang, X.-Y. Li, et al., “Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease,” Molecular Therapy 25 (2017): 752-764.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.